China approves first commercial brain chip for disability treatment

China has become the first country to approve a brain implant for commercial sale to treat disabilities. The device, NEO from Neuracle Medical Technology, enables paralyzed individuals to control a robotic hand using their thoughts. This move contrasts with slower progress in clinical trials in the United States and Europe.

China has achieved a milestone in brain-computer interface technology by approving the first commercially available brain chip designed to address disabilities. Developed by Neuracle Medical Technology, the implant named NEO allows users with paralysis to translate their thoughts into movements of an assistive robotic hand. This approval marks China as the pioneering nation in bringing such a device to market for sale, as stated in reports from WIRED published on March 20, 2026. The development highlights China's aggressive push toward commercialization in the sector, while the United States and Europe proceed more cautiously with ongoing clinical trials for similar brain implants. Keywords associated with the story include brain-computer interfaces, neuroscience, and comparisons to companies like Neuralink. This advancement underscores differing regulatory approaches globally, with China aiming to lead the industry, according to the article's title. No specific details on approval timelines or further trials were provided in the source material.

Liittyvät artikkelit

Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
AI:n luoma kuva

Health ministry panel conditionally approves iPS cell products

Raportoinut AI AI:n luoma kuva

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Three rhesus macaque monkeys equipped with brain-computer interfaces navigated virtual environments using only their thoughts. Researchers implanted around 300 electrodes in motor and premotor cortex areas to enable this control. The experiments aim to improve intuitive control for people with paralysis.

Raportoinut AI

Epia Neuro, a newly launched startup in San Francisco, is developing a brain-computer interface to help stroke patients regain hand movement. The system combines a brain implant with a motorized glove. Stroke remains a leading cause of long-term disability, affecting hand and arm function in about two-thirds of survivors.

Aging societies worldwide face rising demand for elder care amid caregiver shortages. In China, robots in care facilities assist with reminders, medication schedules, and vital sign monitoring. In Latin America, including Cuba, adoption of these technologies remains in early stages but shows promise in complementing family care.

Raportoinut AI

Researchers at the University of Hong Kong have developed a world-first nasal spray that delivers neurotherapeutic powder directly to the brain as first aid for ischemic stroke patients. The treatment, named NanoPowder, is designed to reduce brain damage by more than 80 per cent and improve stroke survival rates. Clinical trials are expected by 2030.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää